The determination of the HER2 status in patients with advanced GC is crucial in order to select patients who may benefit from the new anti-HER2 agents; the results of this study, if confirmed in a prospective larger series, could improve the understanding of molecular interactions between HER2 and E-cad and define their role as predictive factors for targeted therapy. Here, ERBB2 is linked to gastric cancer.